Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | SLC5A7 | Q9GZV3 | 7/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25115724 | 0.86 | PDE4A (0.33) | PDE4APDE4BPDE4CPDE4DNAMPT | |
| SCHEMBL26568540 | 0.83 | SLC5A7 (0.33) | PDE4APDE4BPDE4CPDE4DNAMPT | |
| SCHEMBL26544525 | 0.81 | LMNA (0.33) | NAMPTMAPTLMNA | |
| SCHEMBL24984669 | 0.79 | GABRA5 (0.35) | NAMPTMAPTLMNA | |
| SCHEMBL25113867 | 0.78 | MAPT (0.35) | NAMPTMAPTTHRBLMNATP53 | |
| SCHEMBL24986890 | 0.78 | ALDH1A1 (0.36) | NAMPTLMNATP53POLB | |
| SCHEMBL25114718 | 0.78 | PDE4A (0.35) | PDE4APDE4BPDE4CPDE4DNAMPT | |
| SCHEMBL25113849 | 0.78 | PDE4A (0.35) | PDE4APDE4BPDE4CPDE4DNAMPT | |
| SCHEMBL26532562 | 0.76 | MEN1 (0.39) | PDE4BEPHX2MAPTLMNA | |
| SCHEMBL25116085 | 0.72 | PDE4B (0.35) | PDE4APDE4BPDE4CPDE4DEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | PDE4A 961/4885PDE4B 778/4885PDE4C 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.